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Rationale
VTX-378/1463 are selective TLR8 agonists that interact
with monocytes, macrophages, and myeloid dendritic
cells. We hypothesized that delivery of VTX via nasal
spray directly to sites of allergic inflammation might
initiate rapid anti-allergic activity.
Methods
(Dog) Ragweed (RW)-sensitized dogs (n=5) were treated
with VTX-378 (100, 500 or 1000 μg/dog), given ~ 24
hours prior to RW challenge. Two VTX-378 pretreat-
ments of 250 or 1000 μg/dog, spaced either 3, 4 or 7 days
apart were also evaluated. Changes in nasal cavity volumes
(congestion) were determined by acoustic rhinometry.
(Human) Subsequently, a randomized, double blind, pla-
cebo-controlled study was conducted in-season, and
enrolled 80 adults with confirmed atopy to grass pollen.
Two dosing regimens were compared to placebo: ascend-
ing dose (GrpA; 25, 50, 75, 100 μg) and fixed dose (GrpB;
62.5 μg x 4 doses). Subjects were dosed on Days 1, 8, 15,
and 22 with VTX-1463. On day 24, subjects underwent
grass allergen exposure. The primary endpoints were the
average change over 6 hours of allergen exposure in Total
Nasal Symptom Score (TNSS; sum of scores for nasal con-
gestion, itching, sneezing and rhinorrhea) and Active
Anterior Rhinometry (ARR).
Results
(Dog) Statistically significant improvements in nasal con-
gestion (44.5% ± 8.7%, 59.1% ± 15.1% and 56.5% ± 10.0%
increase in nasal cavity volume vs vehicle) were seen at
100, 500 and 1000 μg/dog doses, respectively, following
24 hour pretreatment. Two 250 μg/dog doses at Day -4
and Day -1, resulted in efficacy comparable to a single
500 μg/dog dose given at Day -1 (58.9% ± 10.3% versus
59.1% ± 15.1%). At a dose of 1000 μg/dog, VTX-378,
pretreatment on Days -8 and -1, Days -5 and -1 or only
Day -1 significantly attenuated nasal congestion (71.9% ±
7.7%, 65.4% ± 10.3% and 56.5% ± 10.0%, respectively).
(Human) Significant improvements in TNSS were
observed in both GrpA (p=0.008) and GrpB (p=0.012).
AAR trended towards a benefit in both groups but did
not reach statistical significance.
Conclusions
Overall, VTX conferred clinical benefit in a dose-depen-
dent manner in both the preclinical dog allergen challenge
model and the human allergen challenge chamber studies.
These findings suggest that in the context of nasal allergies
the dog model can be predictive of dose and clinical
efficacy.
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